Antibodies are essential molecules for diagnosis and treatment of diseases caused by
pathogens and their toxins. Antibodies were integrated in our medical repertoire against …

Antibodies have been used to prevent or treat viral infections since the nineteenth century,
but the full potential to use passive immunization for infectious diseases has yet to be …

Several severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccines are being
deployed, but the global need greatly exceeds the supply, and different formulations might …

A major challenge in managing acute viral infections is ameliorating disease when treatment
is delayed. Previously, we reported the success of a 2-pronged mAb and antiviral remdesivir …

Obeldesivir (ODV, GS-5245) is an orally administered prodrug of the parent nucleoside of
remdesivir (RDV) and is presently in phase 3 trials for COVID-19 treatment. In this work, we …

COVID-19 is a severe acute respiratory disease caused by SARS-CoV-2, a new recently
emerged sarbecovirus. This virus uses the human ACE2 enzyme as receptor for cell entry …

Ebolaviruses cause a severe and often fatal illness with the potential for global spread.
Monoclonal antibody-based treatments that have become available recently have a narrow …

A new vectored vaccine MVA-VLP-SUDV was generated against Sudan ebolavirus (SUDV)
combining the advantages of the immunogenicity of a live attenuated vaccine vector …

Introduction Due to their faithful recapitulation of human disease, nonhuman primates
(NHPs) are considered the gold standard for evaluating drugs against Ebolavirus and other …

Viruses are widespread in the environment, and many of them are major pathogens of
serious plant, animal, and human diseases. The risk of pathogenicity, together with the …